LONDON, Sept. 6, 2016 /PRNewswire/ -- The incidence of
neurological disorders is escalating and the lack of early diagnostic techniques places the spotlight on innovations in this
space. While software platforms are available for processing neuroimaging data, there are limited algorithms for diagnostic and
clinical analyses. However, several cloud-based storage platforms exist for exchange and analyses of a vast amount of global
neurological data. As companies look to develop quantitative software techniques for the detection and analyses of various
neuropathologies, neuroinformatics is poised for a growth spurt in the near future.
The new study, Diagnostic breakthroughs for neurodegenerative
diseases (http://frost.ly/qs), a part of the
TechVision (Medical Devices & Imaging) subscription, finds that while neuroimaging techniques continue to be the gold
standard for neurodiagnostic applications, innovations in biomarker-based diagnostics and integrated neuroinformatic tools will
drive the future of this sector. Clinical neuropathologies such as Alzheimer's and Parkinson's diseases are likely to have the
largest market impact on diagnostics in the near future.
To request exclusive information about this research and to schedule your one-on-one strategy dialogue with our analysts now,
please click here or send an email to Jana
Schöneborn, jana.schoeneborn@frost.com.
There is an increased collaboration between the pharmaceutical and diagnostic sectors for patient selection during clinical
trials, which is fueling the growth of the companion diagnostic market for neurological disorders. This means that the companion
diagnostic market will mirror the growth pattern of the cancer diagnostic sector, expanding the opportunities for diagnostics
developers. Advancements in biomarker studies will aid in early diagnosis and enable timely clinical interventions.
"As it is difficult to offer a conclusive diagnosis using a single technique, neuroimaging techniques are most often used in
combination with other technologies or as an adjunct to the clinical diagnosis of neurological diseases," said TechVision
Research Analyst Vandana Iyer. "Besides, there are very few software platforms that can
integrate and accurately analyze the data obtained from a wide variety of neuroimaging modalities."
The need of the hour is convergence across the biomarker, neuroimaging and informatics segments. Innovations that enable
seamless workflow integration across diverse neurodiagnostic modalities will help overcome technological challenges and widen the
reach of the diagnostics. The standardization of global neuroinformatic clusters will further enable data sharing and
analysis.
Currently, several assay platforms are available for the detection of neurological biomarkers, especially for diseases such as
dementia and Alzheimer's Disease. New biomarker discoveries and advanced diagnostic platforms for Parkinson's disease, traumatic
brain injury and other dementias are expected in the near future. An important emerging trend is the use of optical scanning
techniques for detecting retinal biomarkers for neurological diseases.
"Overall, rapid advancements in hybrid neuroimaging platforms have improved the sensitivity and quantitative accuracy of
neurodiagnostic evaluations for numerous neurodegenerative disorders," noted Iyer. "Neuroimaging modalities will continue to be
one of the major neurodiagnostic tools across research and clinical communities."
Frost & Sullivan's global TechVision practice is focused on innovation, disruption and convergence and provides a variety
of technology based alerts, newsletters and research services as well as growth consulting services. Its premier offering, the
TechVision program, identifies and evaluates the most valuable emerging and disruptive technologies enabling products with
near-term potential. A unique feature of the TechVision program is an annual selection of 50 technologies that can generate
convergence scenarios, possibly disrupt the innovation landscape, and drive transformational growth. View a summary of our
TechVision program by clicking on the following link: http://ifrost.frost.com/TechVision_Demo.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation
that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving
visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey
to visionary innovation including research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is unique as it constructs the foundation upon which visionary innovation
becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our
global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector
and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive
technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging
economies?
Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
Diagnostic Breakthroughs for Neurodegenerative Diseases
D6BC
Contact:
Jana Schoneborn
Corporate Communications -- Europe
P: +49 (0)69 77033 43
E: jana.schoeneborn@frost.com
Twitter: @TechVision_FS
Linkedin: www.frost.com/techvisionlinkedin
http://www.frost.com
http://ww2.frost.com/research/techvision
Photo - http://photos.prnasia.com/prnh/20160906/8521605618